Literature DB >> 1206412

Absence of cellular hypersensitivity to muscle and thymic antigens in myasthenia gravis.

W M Behan, P O Behan, J A Simpson.   

Abstract

Humoral antibodies to skeletal muscle and its components and to thymus have been demonstrated in the sera of patients with myasthenia gravis. A role for cellular hypersensitivity to similar antigens in the pathogenesis of the disease has been suggested by some reports of the presence of cellular immunity. A detailed immunological study using muscle and thymic antigens, including those prepared from the patients' own tissues, failed to confirm these findings. It is suggested that previous reports of cellular hypersensitivity represent the demonstration of an epiphenomenon.

Entities:  

Mesh:

Year:  1975        PMID: 1206412      PMCID: PMC492153          DOI: 10.1136/jnnp.38.11.1039

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  50 in total

1.  AN IMMUNOLOGIC SURVEY OF FORTY-EIGHT PATIENTS WITH MYASTHENIA GRAVIS.

Authors:  M M ADNER; J D SHERMAN; C ISE; R S SCHWAB; W DAMESHEK
Journal:  N Engl J Med       Date:  1964-12-24       Impact factor: 91.245

2.  Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis.

Authors:  O Abramsky; A Aharonov; C Webb; S Fuchs
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

3.  Leukocyte response to muscle antigens in myasthenia gravis. Relationship to clinical severity and presence of circulating antibodies.

Authors:  E Kott; G Genkins; A H Rule
Journal:  Neurology       Date:  1973-04       Impact factor: 9.910

4.  Experimental myasthenia gravis, myositis and myocarditis in guinea-pigs immunized with subcellular fractions of calf thymus or calf skeletal muscle in Freund's complete adjuvant.

Authors:  J R Kalden; W G Williamson; W J Irvine
Journal:  Clin Exp Immunol       Date:  1973-01       Impact factor: 4.330

5.  Muscle antibodies in myasthenic mothers and their babies.

Authors:  H J Oosterhuis; T E Feltkamp; H R van der Geld
Journal:  Lancet       Date:  1966-12-03       Impact factor: 79.321

6.  Experimental autoimmune thymitis. An animal model of human myasthenia gravis.

Authors:  G Goldstein; S Whittingham
Journal:  Lancet       Date:  1966-08-06       Impact factor: 79.321

7.  Increased incidence of HL-A 1 and 8 in patients showing IgG or complement coating on their red cells.

Authors:  J A Da Costa; A G White; A C Parker; G B Grigor
Journal:  J Clin Pathol       Date:  1974-05       Impact factor: 3.411

8.  Experimental myasthenia gravis.

Authors:  J M Vetters; J A Simpson; A Folkarde
Journal:  Lancet       Date:  1969-07-05       Impact factor: 79.321

9.  Myasthenia gravis. Antibodies to an acid-soluble antigen in striated muscle.

Authors:  J A Aarli
Journal:  Clin Exp Immunol       Date:  1972-03       Impact factor: 4.330

10.  Delayed hypersensitivity to muscle and thymus in myasthenia gravis and polymyositis.

Authors:  J M Goust; A Castaigne; R Moulias
Journal:  Clin Exp Immunol       Date:  1974-09       Impact factor: 4.330

View more
  5 in total

Review 1.  Cellular autoimmunity to muscle: a review.

Authors:  M Esiri
Journal:  Proc R Soc Med       Date:  1977-05

Review 2.  Immunological features of polymyositis/dermatomyositis.

Authors:  W M Behan; P O Behan
Journal:  Springer Semin Immunopathol       Date:  1985

Review 3.  Phenotypic and functional analysis of lymphocytes in myasthenia gravis.

Authors:  A I Levinson; R P Lisak; B Zweiman; M Kornstein
Journal:  Springer Semin Immunopathol       Date:  1985

4.  Does Toxoplasma cause polymyositis? Report of a case of polymyositis associated with toxoplasmosis and a critical review of the literature.

Authors:  W M Behan; P O Behan; I T Draper; H Williams
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

5.  Association of myasthenia gravis and polymyositis with neoplasia, infection and autoimmune disorders.

Authors:  W M Behan; P O Behan; D Doyle
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.